UY31400A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
UY31400A1
UY31400A1 UY31400A UY31400A UY31400A1 UY 31400 A1 UY31400 A1 UY 31400A1 UY 31400 A UY31400 A UY 31400A UY 31400 A UY31400 A UY 31400A UY 31400 A1 UY31400 A1 UY 31400A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
methyl
allergic
phthalazinone
azepin
Prior art date
Application number
UY31400A
Other languages
English (en)
Inventor
Martin Philip Noble
Leanda Jane Kindon
Simon Teanby Hodgson
Ashley Paul Hancock
Paul Martin Gore
Richard Orlando Brown
Gavin Bone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31400A1 publication Critical patent/UY31400A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion proporciona composiciones acuosas farmacéuticas que comprenden un compuesto que es 4-[4-clorofenil)metil]-2-({(2R)-1-[4-(4-{[3-(hexahidro-1H-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2H)-ftalazinona o una sal suya farmacéuticamente aceptable, y su uso en el tratamiento de diversas enfermedades inflamatorias y/o alérgicas tales como rinitis alérgica.
UY31400A 2007-10-16 2008-10-16 Composiciones farmaceuticas UY31400A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98022607P 2007-10-16 2007-10-16
US5723008P 2008-05-30 2008-05-30

Publications (1)

Publication Number Publication Date
UY31400A1 true UY31400A1 (es) 2009-05-29

Family

ID=40198721

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31400A UY31400A1 (es) 2007-10-16 2008-10-16 Composiciones farmaceuticas

Country Status (6)

Country Link
AR (1) AR068988A1 (es)
CL (1) CL2008003036A1 (es)
PE (1) PE20091089A1 (es)
TW (1) TW200932243A (es)
UY (1) UY31400A1 (es)
WO (1) WO2009050159A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811447D0 (en) * 2008-06-20 2008-07-30 Glaxo Group Ltd Formulations
RU2652352C2 (ru) * 2012-12-17 2018-04-25 Глаксо Груп Лимитед Комбинация левокабастина и флутиказона фуроата для лечения воспалительных и/или аллергических состояний
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
AU2007242842A1 (en) * 2006-04-20 2007-11-01 Glaxo Group Limited 2-substituted 4-benzylphthalazinone derivatives as histamine H1 and H3 antagonists

Also Published As

Publication number Publication date
AR068988A1 (es) 2009-12-23
TW200932243A (en) 2009-08-01
PE20091089A1 (es) 2009-08-24
CL2008003036A1 (es) 2009-05-08
WO2009050159A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
CY2016015I2 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
UY31431A1 (es) Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap)
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
EA200970870A1 (ru) Новое терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
RS50624B (sr) Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidina
CL2007002967A1 (es) Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
CL2012001133A1 (es) Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo.
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
AR092045A1 (es) Combinaciones farmaceuticas
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
EA200970871A1 (ru) Новое терапевтическое применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
MX339932B (es) Sales de 4-[2-[[5-metil-1-(2naftalenil)-1h-pirazol-3-il]oxi]etil]m orfolina.
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA201170512A1 (ru) Композиция для перорального введения
NZ595823A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
GEP20135913B (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression
NZ594556A (en) Carboxamide compounds and methods for using the same
MX2010007426A (es) Composiciones farmaceuticas para tratar trastorno del higado graso.
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
UY31400A1 (es) Composiciones farmaceuticas

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20121120